Plerixafor for Stem Cell Mobilization in Normal Donors
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if treating stem cell donors with
filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of
blood stem cells than filgrastim by itself. Researchers also want to learn if giving both of
these drugs helps donors produce enough stem cells so that only 1 apheresis procedure needs
to be performed.
Researchers will study if using both drugs lowers the risk of the stem cell transplant
recipients developing severe forms graft-versus-host disease (GVHD). GVHD is a condition in
which transplanted tissue (such as blood stem cells) attacks the tissue of the recipient's
body.
The safety and effectiveness of this drug combination will also be studied.
Filgrastim and plerixafor are both designed to help move or "mobilize" the stem cells from
the bone marrow to the blood.